Personalized Diagnostics 2012

Implementing clinical use of personalized diagnostics can stratify patients, give molecular classification of disease, determine the likelihood of occurrence, and recommend the best course of treatment.  These approaches promise to reduce costs in healthcare, improve treatment, and have the potential to provide consumer-driven access to health information.  Technologies will be evaluated for research and clinical use, and approaches for turning these discoveries into viable business models will be highlighted.

Who Should Attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as Diagnostics, Business Development, R&D, Chemistry, Clinical Research, in vitro Diagnostics, Personalized Healthcare, Process Development, and Oncology.

Topics will include, but are not limited to:

-Third generation sequencing as a clinical tool
-Integrating molecular and cell-based diagnostics
-Leveraging epigenetics, gene mutation analysis, and gene expression assays
-Using proteomics as a diagnostic tool
-Mass spec to find and monitor biomarkers in blood
-NGS for mitochondrial disease diagnostics
-Assembling gene panels
-NGS data management
-RNA sequencing